Impact of subgroup classification accuracy on detecting heterogeneous treatment effects in Staphylococcus aureus bacteraemia: A simulation study

The Hidden Cost of Misclassifying Patients

Why do some patients respond to a life-saving antibiotic while others suffer severe side effects or even death? Researchers used computer simulations to see how hard it is to find specific groups of patients who respond differently to treatments for a serious blood infection called Staphylococcus aureus bacteraemia (SAB). They found that if we do not group patients perfectly or choose the right way to measure success, we might miss important life-saving information.

The central challenge in modern medicine is moving from "one size fits all" to stratified medicine (tailoring medical decisions to individual patient characteristics). In SAB, clinicians have identified various "subphenotypes" (distinct clusters of patients with similar clinical traits) that appear to react differently to drugs like rifampicin. However, identifying these subgroups relies on classification algorithms that are rarely 100% accurate. If a diagnostic tool incorrectly assigns a patient to the wrong group, the mathematical foundation of the clinical trial can crumble.

The breakdown of subgroup detection

Current clinical trials often treat SAB as a single entity. This risks missing treatments that could save specific subsets of people. Recent studies have identified five distinct subphenotypes (labeled A through E). Yet, the transition from observing these groups to testing drugs specifically for them is difficult.

Most researchers use post-hoc analysis (analyzing patient groups after a trial is finished) to see if any specific subgroup benefited. The authors of this simulation study argue that this approach is highly sensitive to how well we can sort patients into those groups. If classification is imperfect, the perceived treatment effect becomes "diluted." This is like pouring a drop of dark ink into a gallon of water. The specific signal of the ink is lost to the surrounding volume. Even with a perfect classifier, the authors find that detecting these effects depends heavily on subgroup prevalence (how common the group is) and baseline mortality (how many patients die without treatment).

Simulating the impact of error

To quantify this risk, the researchers used the ADEMP (aims, data generation, estimands, and performance measures) framework to run a series of simulations. They modeled the specific parameters of SAB subgroups derived from actual clinical data, such as the ARREST trial.

The simulation architecture worked in several stages: 1. Generating Ground Truth: The authors created synthetic patient populations with known treatment effects and subgroup frequencies based on historical SAB data. 2. Introducing Noise: They systematically varied the "classification accuracy" from 70% to 100%. This simulates real-world diagnostic tests that are not perfect. 3. Testing Mitigation Strategies: They evaluated "enrichment designs" (where only patients predicted to be in a specific group are allowed into the trial) and "ordinal outcomes" (using a graded scale of recovery rather than a simple "dead or alive" binary measurement).

The researchers looked at how these choices impacted three critical metrics: power (the ability to detect a real effect), Type I error (the risk of seeing an effect that isn't actually there), and bias (how far the estimated effect deviates from the truth).

Measuring the price of inaccuracy

The results highlight a stark divide between different types of patient groups. The authors report that for "Subgroup B"—which has a large treatment effect and moderate prevalence—detection is feasible. Even with perfect classification, they found complete power at a sample size of 3,000 [Table 2].

However, for almost all other subgroups, the news is much bleaker. The paper finds that power remains inadequate even when the trial size reaches 20,000 participants. When classification accuracy drops, the situation worsens significantly. As shown in, decreasing accuracy leads to a substantial loss in power and introduces significant bias.

For rare subgroups with large effects, even minor misclassification pulls the observed estimate toward the population average. This effectively masks the treatment's true utility.

The authors also investigated "enrichment" as a solution. They found that while enrichment helped for Subgroup B, it remained unattractive or infeasible for other subgroups .

This is because the number of patients needing to be screened to find enough valid participants was too high.

The trade-offs of measuring success

One of the most nuanced findings concerns how we define "success" in a trial. Most trials use a binary outcome: did the patient live or die? The authors tested whether an "ordinal outcome" (a scale that ranks severity, such as 1 for death and 6 for full recovery) could perform better.

The effectiveness of this switch depends entirely on the biological mechanism of the drug. The paper finds that if a drug causes a "proportional-odds" effect (meaning it improves the chances of moving up any level of the scale), ordinal outcomes substantially increase power .

However, if the drug only affects mortality (a "death-only" effect), the binary "dead or alive" measure is actually more powerful .

This creates a dilemma for trial designers. There is a push for "core outcome sets" (standardized lists of things every trial must report). But the authors argue that a single standardized outcome cannot be optimal for every drug. A drug that helps clear bacteria might show benefits across the whole recovery spectrum. Conversely, a drug that prevents organ failure might only show a benefit at the mortality threshold.

Verdict: A warning for stratified medicine

Is stratified medicine in SAB ready for widespread use? The answer depends on your precision.

If you are targeting a common subgroup with a massive treatment effect and a highly accurate biomarker, the path is clear. But for the majority of rare or subtle subphenotypes, current methods are likely to fail. The authors suggest that researchers should move toward "mechanism-matched" outcomes and more robust, biomarker-driven classifiers.

Code for this simulation framework is reportedly available; see the paper for the canonical link at https://github.com/gushamilton/sab_het. For those looking to prototype new trial designs, the takeaway is clear: do not just pick an outcome because it is standard. Pick it because it matches how you expect the drug to work.

Figures from the paper